126 related articles for article (PubMed ID: 24329588)
21. Diagnosis of prostate cancer with needle biopsy: should all cases be biopsied before treatment?
Oranusi CK; Ugezu AI; Nwofor A
Niger J Clin Pract; 2012; 15(1):48-50. PubMed ID: 22437089
[TBL] [Abstract][Full Text] [Related]
22. [Epidemiological trends in prostate cancer over the last years].
Luján Galán M; Páez Borda A; Chiva Robles V; Santonja Garriga C; Romero Cajigal I; Berenguer Sánchez A
Arch Esp Urol; 2004 Oct; 57(8):817-25. PubMed ID: 15560270
[TBL] [Abstract][Full Text] [Related]
23. A sex difference in the hypothalamic uncinate nucleus: relationship to gender identity.
Garcia-Falgueras A; Swaab DF
Brain; 2008 Dec; 131(Pt 12):3132-46. PubMed ID: 18980961
[TBL] [Abstract][Full Text] [Related]
24. Fracture risk following bilateral orchiectomy.
Melton LJ; Alothman KI; Khosla S; Achenbach SJ; Oberg AL; Zincke H
J Urol; 2003 May; 169(5):1747-50. PubMed ID: 12686824
[TBL] [Abstract][Full Text] [Related]
25. Risk of hormonotherapy in transgender people: Literature review and data from the French Database of Pharmacovigilance.
Bourgeois AL; Auriche P; Palmaro A; Montastruc JL; Bagheri H
Ann Endocrinol (Paris); 2016 Feb; 77(1):14-21. PubMed ID: 26830952
[TBL] [Abstract][Full Text] [Related]
26. First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.
Prescrire Int; 2013 Feb; 22(135):48-51. PubMed ID: 23444510
[TBL] [Abstract][Full Text] [Related]
27. [PSA testing, biopsy and cancer and benign prostate hyperplasia in France].
Tuppin P; Samson S; Fagot-Campagna A; Lukacs B; Alla F; Allemand H; Paccaud F; Thalabard JC; Vicaut E; Vidaud M; Millat B
Prog Urol; 2014 Jul; 24(9):572-80. PubMed ID: 24975792
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer in Maiduguri.
Yawe KT; Tahir MB; Nggada HA
West Afr J Med; 2006; 25(4):298-300. PubMed ID: 17402521
[TBL] [Abstract][Full Text] [Related]
29. [Our experience with hormonal therapy in transsexual patients].
Weiss V; Weiss P; Fifková H
Vnitr Lek; 2015 Mar; 61(3):197-201. PubMed ID: 25873114
[TBL] [Abstract][Full Text] [Related]
30. Endocrine prevention and treatment of prostate cancer.
Tammela TL
Mol Cell Endocrinol; 2012 Sep; 360(1-2):59-67. PubMed ID: 22465099
[TBL] [Abstract][Full Text] [Related]
31. Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal follow-up from a prospective trial.
Ploussard G; Nicolaiew N; Marchand C; Terry S; Allory Y; Vacherot F; Abbou CC; Salomon L; de la Taille A
BJU Int; 2013 May; 111(6):988-96. PubMed ID: 23452046
[TBL] [Abstract][Full Text] [Related]
32. Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia.
Ranasinghe WK; Kim SP; Lawrentschuk N; Sengupta S; Hounsome L; Barber J; Jones R; Davis P; Bolton D; Persad R
BJU Int; 2014 Jan; 113(1):77-83. PubMed ID: 24053128
[TBL] [Abstract][Full Text] [Related]
33. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
[TBL] [Abstract][Full Text] [Related]
34. The impact of birth weight on prostate cancer incidence and mortality in a population-based study of men born in 1913 and followed up from 50 to 85 years of age.
Eriksson M; Wedel H; Wallander MA; Krakau I; Hugosson J; Carlsson S; Svärdsudd K
Prostate; 2007 Aug; 67(11):1247-54. PubMed ID: 17570499
[TBL] [Abstract][Full Text] [Related]
35. [Hormonal treatment of transsexual persons].
Tinkanen H; Das P
Duodecim; 2015; 131(4):372-8. PubMed ID: 26237927
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
Nanda A; Chen MH; Moran BJ; Braccioforte MH; Dosoretz D; Salenius S; Katin M; Ross R; D'Amico AV
Eur Urol; 2014 Jan; 65(1):177-85. PubMed ID: 22981136
[TBL] [Abstract][Full Text] [Related]
37. Metabolic syndrome and androgen deprivation therapy in metabolic complications of prostate cancer patients.
Yuan JQ; Xu T; Zhang XW; Yu LP; Li Q; Liu SJ; Huang XB; Wang XF
Chin Med J (Engl); 2012 Oct; 125(20):3725-9. PubMed ID: 23075732
[TBL] [Abstract][Full Text] [Related]
38. Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer.
Ost P; Decaestecker K; Lambert B; Fonteyne V; Delrue L; Lumen N; Ameye F; De Meerleer G
Prostate; 2014 Feb; 74(3):297-305. PubMed ID: 24395565
[TBL] [Abstract][Full Text] [Related]
39. Hormone-treated transsexuals report less social distress, anxiety and depression.
Gómez-Gil E; Zubiaurre-Elorza L; Esteva I; Guillamon A; Godás T; Cruz Almaraz M; Halperin I; Salamero M
Psychoneuroendocrinology; 2012 May; 37(5):662-70. PubMed ID: 21937168
[TBL] [Abstract][Full Text] [Related]
40. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891).
Studer UE; Collette L; Whelan P; Albrecht W; Casselman J; de Reijke T; Knönagel H; Loidl W; Isorna S; Sundaram SK; Debois M;
Eur Urol; 2008 May; 53(5):941-9. PubMed ID: 18191322
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
